Graft-Versus-Host Disease Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Epidemiology, Medication, NDA Approvals, Pipeline, Therapeutics and Companies by DelveInsight

Graft-Versus-Host Disease Companies in the treatment market are CSL Behring, Equillium, Biocon, MaaT Pharma, Regimmune, Jazz Pharmaceuticals, Pharmacyclics LLC., Novartis, Biogen, Mallinckrodt, Astellas Pharma, Mesoblast, Inc., Thrasher Research Fund, Regimmune Corporation, Syndax Pharmaceutical, Novartis, and others.
(Albany, USA) DelveInsight's "Graft-Versus-Host Disease Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Graft-Versus-Host Disease, historical and forecasted epidemiology as well as the Graft-Versus-Host Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The Graft-Versus-Host Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Graft-Versus-Host Disease pipeline products will significantly revolutionize the Graft-Versus-Host Disease market dynamics.

To Know in detail about the Graft-Versus-Host Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Graft-Versus-Host Disease Market Forecast [https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Some of the key facts of the Graft-Versus-Host Disease Market Report:

*
The Graft-Versus-Host Disease market size was valued approximately ~USD 1100 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

*
The only FDA-approved therapies for treating GvHD are ORENCIA (abatacept), JAKAFI/JAKAVI (ruxolitinib), IMBRUVICA (ibrutinib), and REZUROCK (belumosudil).

*
In 2023, there were approximately 25,000 hematopoietic stem-cell transplant cases and around 10,500 allogenic transplant cases in the US.

*
In 2023, the US had the largest Graft vs. Host Disease population, making up about 45% of the total in the 7MM. Japan contributed around 16%, while Germany accounted for approximately 15% of the population share.

*
Chronic graft-versus-host disease (GvHD) severity is categorized as mild, moderate, or severe based on the number and severity of affected organs. About 45% of the five-year prevalent cases of this chronic condition are classified as moderate.

*
Key Graft-Versus-Host Disease Companies: CSL Behring, Equillium, Biocon, MaaT Pharma, Regimmune, Jazz Pharmaceuticals, Pharmacyclics LLC., Novartis, Biogen, Mallinckrodt, Astellas Pharma, Mesoblast, Inc., Thrasher Research Fund, Regimmune Corporation, Syndax Pharmaceutical, Novartis, and others

*
Key Graft-Versus-Host Disease Therapies: ZEMAIRA (CSL 964, alpha-1 antitrypsin), EQ001 (itolizumab; Bmab600), MaaT013, RGI-2001, Defibrotide, Ibrutinib, Panobinostat (LBH589), Natalizumab, Methoxsalen, Prograf, Prochymal Registered , Abatacept, RGI-2001, Axatilimab, Ruxolitinib, and others

*
In the United States in 2022, roughly 4,780 cases of acute Graft-versus-host disease (aGvHD) and approximately 17,210 cases of chronic Graft-versus-host disease (cGvHD) received first-line treatment. Projections suggest an anticipated increase in these cases by the year 2034.

*
The Graft-Versus-Host Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Graft-Versus-Host Disease pipeline products will significantly revolutionize the Graft-Versus-Host Disease market dynamics.

Graft-Versus-Host Disease Overview

Graft-versus-host disease (GVHD) is a serious complication that occurs after an allogeneic hematopoietic stem cell transplant (HSCT), where the donated immune cells recognize the recipient's tissues as foreign and attack them. GVHD primarily affects the skin, liver, and gastrointestinal tract and is a leading cause of morbidity and mortality in transplant recipients.

GVHD is classified into acute GVHD (aGVHD) and chronic GVHD (cGVHD). Acute GVHD typically occurs within the first 100 days post-transplant and presents with symptoms such as skin rash, liver dysfunction, and gastrointestinal distress, including nausea, vomiting, and diarrhea. Chronic GVHD, which can develop months or years after transplantation, resembles autoimmune disorders and can affect multiple organs, leading to fibrosis, joint stiffness, and lung complications.

Diagnosis is based on clinical presentation, biopsy findings, and laboratory tests. Management involves immunosuppressive therapies such as corticosteroids, calcineurin inhibitors (e.g., tacrolimus, cyclosporine), and biologic agents like ruxolitinib. Preventive strategies, including optimized donor selection and prophylactic immunosuppressants, play a crucial role in reducing GVHD risk. Ongoing research is focused on developing novel therapies, including cellular therapies and targeted immunomodulators, to improve treatment outcomes and enhance the quality of life for patients affected by GVHD.

Get a Free sample for the Graft-Versus-Host Disease Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market [https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Graft-Versus-Host Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Graft-Versus-Host Disease Epidemiology Segmentation:

The Graft-Versus-Host Disease market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Graft-Versus-Host Disease

*
Prevalent Cases of Graft-Versus-Host Disease by severity

*
Gender-specific Prevalence of Graft-Versus-Host Disease

*
Diagnosed Cases of Episodic and Chronic Graft-Versus-Host Disease

Download the report to understand which factors are driving Graft-Versus-Host Disease epidemiology trends @ Graft-Versus-Host Disease Epidemiology Forecast [https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Graft-Versus-Host Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Graft-Versus-Host Disease market or expected to get launched during the study period. The analysis covers Graft-Versus-Host Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Graft-Versus-Host Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Graft-Versus-Host Disease Therapies and Key Companies

*
ZEMAIRA (CSL 964, alpha-1 antitrypsin): CSL Behring

*
EQ001 (itolizumab; Bmab600): Equillium/Biocon

*
CSL 964 AAT (zemaira): CSL Behring

*
MaaT013: MaaT Pharma

*
RGI-2001: Regimmune

*
Defibrotide: Jazz Pharmaceuticals

*
Ibrutinib: Pharmacyclics LLC.

*
Panobinostat (LBH589): Novartis

*
Natalizumab: Biogen

*
Methoxsalen: Mallinckrodt

*
Prograf: Astellas Pharma

*
Prochymal Registered : Mesoblast, Inc.

*
Abatacept: Thrasher Research Fund

*
RGI-2001: Regimmune Corporation

*
Axatilimab: Syndax Pharmaceutical

*
Ruxolitinib: Novartis

Discover more about therapies set to grab major Graft-Versus-Host Disease market share @ Graft-Versus-Host Disease Treatment Landscape [https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Graft-Versus-Host Disease Market Strengths

Pipeline of GvHD is very robust and several late stage assets are expected to enter in to the market very soon. GvHD pipeline consists of small molecules, monoclonal and Bi-specific antibody, stem cell therapy, recombinant fusion protein etc. which will provide the patients and physicians more options in future.

Graft-Versus-Host Disease Market Opportunities

Several upcoming therapies have received Orphan designations, therapies can get accelerated approval time, 7 years of market exclusivity in the US, clinical trials subsidies and reduced regulatory fees and others. Company can also go for premium pricing as well.

Scope of the Graft-Versus-Host Disease Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Graft-Versus-Host Disease Companies: CSL Behring, Equillium, Biocon, MaaT Pharma, Regimmune, Jazz Pharmaceuticals, Pharmacyclics LLC., Novartis, Biogen, Mallinckrodt, Astellas Pharma, Mesoblast, Inc., Thrasher Research Fund, Regimmune Corporation, Syndax Pharmaceutical, Novartis, and others

*
Key Graft-Versus-Host Disease Therapies: ZEMAIRA (CSL 964, alpha-1 antitrypsin), EQ001 (itolizumab; Bmab600), MaaT013, RGI-2001, Defibrotide, Ibrutinib, Panobinostat (LBH589), Natalizumab, Methoxsalen, Prograf, Prochymal Registered , Abatacept, RGI-2001, Axatilimab, Ruxolitinib, and others

*
Graft-Versus-Host Disease Therapeutic Assessment: Graft-Versus-Host Disease current marketed and Graft-Versus-Host Disease emerging therapies

*
Graft-Versus-Host Disease Market Dynamics: Graft-Versus-Host Disease market drivers and Graft-Versus-Host Disease market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Graft-Versus-Host Disease Unmet Needs, KOL's views, Analyst's views, Graft-Versus-Host Disease Market Access and Reimbursement

To know more about Graft-Versus-Host Disease companies working in the treatment market, visit @ Graft-Versus-Host Disease Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Table of Contents

1. Graft-Versus-Host Disease Market Report Introduction

2. Executive Summary for Graft-Versus-Host Disease

3. SWOT analysis of Graft-Versus-Host Disease

4. Graft-Versus-Host Disease Patient Share (%) Overview at a Glance

5. Graft-Versus-Host Disease Market Overview at a Glance

6. Graft-Versus-Host Disease Disease Background and Overview

7. Graft-Versus-Host Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Graft-Versus-Host Disease

9. Graft-Versus-Host Disease Current Treatment and Medical Practices

10. Graft-Versus-Host Disease Unmet Needs

11. Graft-Versus-Host Disease Emerging Therapies

12. Graft-Versus-Host Disease Market Outlook

13. Country-Wise Graft-Versus-Host Disease Market Analysis (2020-2034)

14. Graft-Versus-Host Disease Market Access and Reimbursement of Therapies

15. Graft-Versus-Host Disease Market Drivers

16. Graft-Versus-Host Disease Market Barriers

17. Graft-Versus-Host Disease Appendix

18. Graft-Versus-Host Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=graftversushost-disease-treatment-market-2034-ema-pdma-fda-approvals-clinical-trials-epidemiology-medication-nda-approvals-pipeline-therapeutics-and-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.